Raymond James Financial
AVXL icon

Raymond James Financial’s Anavex Life Sciences AVXL Stock Holding History

Raymond James Financial’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.5K Sell
12,943
-9,490
-42% -$28.1K ﹤0.01% 5297
2026
Q1 		$68.9K Buy
22,433
+5,777
+35% +$25K ﹤0.01% 5089
2025
Q4 		$59.3K Sell
16,656
-5,289
-24% -$32.4K ﹤0.01% 4992
2025
Q3 		$195K Sell
21,945
-185
-0.8% -$1.88K ﹤0.01% 4630
2025
Q2 		$204K Buy
22,130
+5,000
+29% +$42.7K ﹤0.01% 4504
2025
Q1 		$147K Buy
17,130
+1,546
+10% +$14.6K ﹤0.01% 4483
2024
Q4 		$167K Buy
+15,584
New +$120K ﹤0.01% 4445

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial's AVXL Position: Q2 2026 in Review

Raymond James Financial reduced its Anavex Life Sciences (AVXL) stake by 42% in Q2 2026, selling an estimated $28.1K and leaving 12,943 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5297.

Raymond James Financial first reported a position in AVXL in Q4 2024 and has held it in 7 quarters since. The position peaked at $204K in Q2 2025. 180 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Raymond James Financial held 12,943 shares of Anavex Life Sciences worth $33.5K as of Q2 2026.
  • Raymond James Financial sold 9,490 Anavex Life Sciences shares in Q2 2026, an estimated $28.1K.
  • Anavex Life Sciences made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5297 holding.
  • Raymond James Financial first reported a position in Anavex Life Sciences in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Anavex Life Sciences position peaked at $204K in Q2 2025.
  • 180 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.